1513 related articles for article (PubMed ID: 23658459)
21. Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.
Lim SM; Kim HR; Shim HS; Soo RA; Cho BC
Future Oncol; 2013 Mar; 9(3):377-86. PubMed ID: 23469973
[TBL] [Abstract][Full Text] [Related]
22. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
[TBL] [Abstract][Full Text] [Related]
24. Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.
Brown WS; Tan L; Smith A; Gray NS; Wendt MK
Mol Cancer Ther; 2016 Sep; 15(9):2096-106. PubMed ID: 27371729
[TBL] [Abstract][Full Text] [Related]
25. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER
Mao P; Cohen O; Kowalski KJ; Kusiel JG; Buendia-Buendia JE; Cuoco MS; Exman P; Wander SA; Waks AG; Nayar U; Chung J; Freeman S; Rozenblatt-Rosen O; Miller VA; Piccioni F; Root DE; Regev A; Winer EP; Lin NU; Wagle N
Clin Cancer Res; 2020 Nov; 26(22):5974-5989. PubMed ID: 32723837
[TBL] [Abstract][Full Text] [Related]
26. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
Kim HR; Kang HN; Shim HS; Kim EY; Kim J; Kim DJ; Lee JG; Lee CY; Hong MH; Kim SM; Kim H; Pyo KH; Yun MR; Park HJ; Han JY; Youn HA; Ahn MJ; Paik S; Kim TM; Cho BC
Ann Oncol; 2017 Jun; 28(6):1250-1259. PubMed ID: 28460066
[TBL] [Abstract][Full Text] [Related]
27. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
[TBL] [Abstract][Full Text] [Related]
28. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
[TBL] [Abstract][Full Text] [Related]
29. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
30. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
Huynh H; Chow PK; Tai WM; Choo SP; Chung AY; Ong HS; Soo KC; Ong R; Linnartz R; Shi MM
J Hepatol; 2012 Mar; 56(3):595-601. PubMed ID: 22027573
[TBL] [Abstract][Full Text] [Related]
31. Differential distribution of fibroblast growth factor receptors (FGFRs) on foveal cones: FGFR-4 is an early marker of cone photoreceptors.
Cornish EE; Natoli RC; Hendrickson A; Provis JM
Mol Vis; 2004 Jan; 10():1-14. PubMed ID: 14737068
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
Wan X; Corn PG; Yang J; Palanisamy N; Starbuck MW; Efstathiou E; Li Ning Tapia EM; Zurita AJ; Aparicio A; Ravoori MK; Vazquez ES; Robinson DR; Wu YM; Cao X; Iyer MK; McKeehan W; Kundra V; Wang F; Troncoso P; Chinnaiyan AM; Logothetis CJ; Navone NM
Sci Transl Med; 2014 Sep; 6(252):252ra122. PubMed ID: 25186177
[TBL] [Abstract][Full Text] [Related]
33. FGF receptors: cancer biology and therapeutics.
Katoh M; Nakagama H
Med Res Rev; 2014 Mar; 34(2):280-300. PubMed ID: 23696246
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of Primary Drug Resistance in
Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
[No Abstract] [Full Text] [Related]
35. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE.
Tannheimer SL; Rehemtulla A; Ethier SP
Breast Cancer Res; 2000; 2(4):311-20. PubMed ID: 11056689
[TBL] [Abstract][Full Text] [Related]
36. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
[TBL] [Abstract][Full Text] [Related]
37. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
[TBL] [Abstract][Full Text] [Related]
38. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
Malchers F; Dietlein F; Schöttle J; Lu X; Nogova L; Albus K; Fernandez-Cuesta L; Heuckmann JM; Gautschi O; Diebold J; Plenker D; Gardizi M; Scheffler M; Bos M; Seidel D; Leenders F; Richters A; Peifer M; Florin A; Mainkar PS; Karre N; Chandrasekhar S; George J; Silling S; Rauh D; Zander T; Ullrich RT; Reinhardt HC; Ringeisen F; Büttner R; Heukamp LC; Wolf J; Thomas RK
Cancer Discov; 2014 Feb; 4(2):246-57. PubMed ID: 24302556
[TBL] [Abstract][Full Text] [Related]
39. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
Azuma K; Tsurutani J; Sakai K; Kaneda H; Fujisaka Y; Takeda M; Watatani M; Arao T; Satoh T; Okamoto I; Kurata T; Nishio K; Nakagawa K
Biochem Biophys Res Commun; 2011 Apr; 407(1):219-24. PubMed ID: 21377448
[TBL] [Abstract][Full Text] [Related]
40. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.
Zhang H; Hylander BL; LeVea C; Repasky EA; Straubinger RM; Adjei AA; Ma WW
Br J Cancer; 2014 Jan; 110(2):320-9. PubMed ID: 24327018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
